Capital Markets Day

hVIVO PLC

20 May 2026

 

hVIVO plc

("hVIVO", the "Company" or the "Group")

hVIVO to showcase integrated, full service early clinical development platform at Capital Markets Day

Speakers from Boehringer Ingelheim, RA Capital, ILiAD Biotechnologies and Decoy Therapeutics to discuss hVIVO's clinical development offering

London, UK - 20 May 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that it will hold a Capital Markets Day for analysts, institutional investors and media in Canary Wharf on Thursday 11 June 2026 from 09:00 - 13:00 (BST).

The event will provide investors with a deeper understanding of hVIVO's strategic evolution from a specialist human challenge trial provider into a differentiated, integrated early clinical development partner, supporting biotechnology and pharmaceutical companies from preclinical strategy through first-in-human studies, patient trials and specialist laboratory services.

Through presentations from clients, investors, industry experts and hVIVO leadership, the event will explore how the Company's end-to-end platform is helping sponsors generate high-quality data earlier, accelerate development timelines and reduce execution risk across the clinical development pathway.

The programme will feature real-world case studies, including on hVIVO's role in supporting Cidara Therapeutics' drug development strategy leading to a $9 billion exit, and a presentation from ILiAD Biotechnologies on the world's first Phase III pivotal human challenge trial.

Discussions will also explore emerging investment trends in infectious disease, the strategic value of human challenge trials, the increasing importance of specialist partners in early drug development across Big Pharma and biotech, and how hVIVO's integrated platform supports faster, more informed development decisions.

External speakers will include:

·    Mario Barro, PhD, Head of Infectious Diseases, RA Capital

·    Stephanie Noviello, Chief Medical Officer, ILiAD Biotechnologies

·    Corrina Pavetto, ClinReg Consulting, LLC (formerly SVP Clinical Development, Cidara Therapeutics)

·    Konstantinos Sinogiannis, Global Category Manager, Boehringer Ingelheim

·    Rick Pierce, Chief Executive Officer, Decoy Therapeutics

·    Professor Richard Russell, Head of Immunobiology, Professor of Respiratory Medicine, King's College London

·    Dr Diane Gbesemete, Clinical Research Fellow, University Hospital Southampton

The event will conclude with the opportunity for attendees to tour hVIVO's Canary Wharf quarantine facility and laboratories.

Analysts, institutional investors and media are welcome to attend the event in-person. Due to capacity constraints, attendance will be limited, however, a recording of the presentation will be made available on the Company's website shortly after the event.

To register your interest for the Capital Markets Day, please email [e-mail].

For further information please contact:

hVIVO plc		[phone]
Yamin 'Mo' Khan, Chief Executive Officer Stephen Pinkerton, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)				[phone]
Geoff Nash, Callum Davidson Trisyia Jamaludin, Harriet Ward Nigel Birks - Life Science Specialist Sales Louise Talbot - Sales
Peel Hunt LLP (Joint Broker)			[phone]
James Steel, Dr Christopher Golden
Davy (Joint Broker)			[phone]
Anthony Farrell, Niall Gilchrist
ICR Healthcare (Financial PR & IR) Mary-Jane Elliott / Stephanie Cuthbert / Phillip Marriage / Louis Ashe-Jepson		[e-mail]

Notes to Editors

hVIVO plc (AIM: HVO) is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world's ten largest biopharma companies.

The Company has an end-to-end platform designed to bring important medicines to patients faster: spanning preclinical strategy, first‑in‑human studies, Phase II patient trials and specialist laboratory services, delivered through a large participant database, wholly owned sites and laboratories across the UK and Germany.

With a combined Group heritage of more than 100 years, hVIVO delivers an accelerated pathway to clinical proof-of-concept through four integrated service lines: Consulting, Clinical Trials, Human Challenge Trials, and Laboratories.

·    Consulting provides expert-led preclinical and clinical strategy, encompassing non-clinical, clinical, CMC, pharmacokinetics, data management, biostatistics, and regulatory support to guide trial design, execution, and interpretation.

·    Clinical Trials offers Phase I/II CRO services, Phase II/III site services across the UK and Germany, and specialist recruitment through FluCamp, Europe's largest recruitment database.

·    Human Challenge Trials leverages hVIVO's state-of-the-art quarantine facility in London - the largest of its kind worldwide - to deliver fast, controlled, high-quality efficacy data through guaranteed viral exposure.

·    Laboratories provides cutting-edge virology and immunology laboratory services, including biobanking and sample storage, supporting both challenge trials and standalone client studies.

 

END